Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Photo: Spar Nord/PR

It's a hard blow for Orphazyme that the US Food and Drug Administration (FDA) has rejected the biotech firm's main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C (NPC).

In connection with the verdict, the biotech company communicates that it is downgrading its guidance for 2021, and the company CEO says that corporate costs will be reviewed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs